Related Experiment Video
Updated: Oct 28, 2026

Coincubation Assay for Quantifying Competitive Interactions between Vibrio fischeri Isolates
Published on: July 22, 2019
Quantitative Proteomic Analysis Reveals That Central Metabolic Pathways Influence Norfloxacin Susceptibility in
Chenghao Shen1,2,3, Yanchang Wu1,2,3, Jiaqi Tang1
1School of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
Abstract:
Reduced antibiotic susceptibility often involves reversible metabolic reprogramming. Here, data-independent acquisition (DIA)-based quantitative proteomics was employed to profile the response of Vibrio alginolyticus (V. alginolyticus) to norfloxacin (NOR) exposure, revealing a global metabolic downshift marked by prominent reductions in central carbon, energy, and amino acid pathways. High-throughput phenotypic screening identified 11 exogenous metabolites, including glycine (Gly) and glutamine (Gln), that significantly potentiated NOR-mediated growth inhibition. Mechanistically, physiological assays demonstrated that glycine supplementation perturbed cellular redox balance, accompanied by elevated reactive oxygen species (ROS) levels and a reduction in the intracellular reduced glutathione (GSH) pool under NOR challenge. Furthermore, mRNA expression analysis (qPCR) revealed that while NOR restricted transcripts of the downstream anaplerotic Gln-to-2-oxoglutarate axis, including the 2-oxoglutarate dehydrogenase complex and NAD+-dependent glutamate dehydrogenase, exogenous Gln supplementation effectively alleviated this transcriptional suppression. Collectively, these findings demonstrate that targeted metabolite supplementation overrides defensive low-flux states, forcing metabolic and transcriptional reactivation that intensifies antibiotic efficacy via ROS-mediated oxidative stress and impairment of antioxidant defense.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Antibiotic Selection
Microbiota Modulation by Antibiotics
Development of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis

